Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| peripheral blood | 13 studies | 25% ± 9% | |
| lung | 11 studies | 24% ± 9% | |
| kidney | 6 studies | 20% ± 4% | |
| intestine | 6 studies | 28% ± 13% | |
| eye | 6 studies | 32% ± 10% | |
| brain | 6 studies | 30% ± 11% | |
| pancreas | 4 studies | 38% ± 7% | |
| bone marrow | 4 studies | 19% ± 4% | |
| uterus | 4 studies | 34% ± 15% | |
| lymph node | 4 studies | 22% ± 4% | |
| breast | 4 studies | 23% ± 3% | |
| liver | 3 studies | 26% ± 14% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| ovary | 100% | 4386.16 | 180 / 180 | 100% | 17.98 | 430 / 430 |
| brain | 100% | 3236.58 | 2641 / 2642 | 100% | 34.62 | 705 / 705 |
| breast | 100% | 3013.43 | 459 / 459 | 100% | 23.70 | 1116 / 1118 |
| uterus | 100% | 3638.75 | 170 / 170 | 100% | 18.49 | 458 / 459 |
| intestine | 100% | 2917.32 | 966 / 966 | 100% | 16.04 | 525 / 527 |
| bladder | 100% | 2992.05 | 21 / 21 | 100% | 15.86 | 502 / 504 |
| thymus | 100% | 1956.00 | 651 / 653 | 100% | 25.29 | 604 / 605 |
| esophagus | 100% | 2469.87 | 1445 / 1445 | 99% | 10.66 | 182 / 183 |
| lung | 99% | 1993.70 | 575 / 578 | 100% | 14.66 | 1154 / 1155 |
| prostate | 100% | 2306.21 | 244 / 245 | 100% | 25.22 | 501 / 502 |
| stomach | 100% | 2061.38 | 359 / 359 | 99% | 14.09 | 284 / 286 |
| adrenal gland | 100% | 2288.00 | 258 / 258 | 99% | 31.36 | 228 / 230 |
| kidney | 100% | 1684.40 | 89 / 89 | 99% | 20.02 | 890 / 901 |
| liver | 98% | 890.84 | 222 / 226 | 100% | 12.63 | 405 / 406 |
| skin | 100% | 2640.00 | 1808 / 1809 | 97% | 16.06 | 459 / 472 |
| pancreas | 97% | 1322.23 | 317 / 328 | 99% | 18.07 | 177 / 178 |
| adipose | 100% | 3235.36 | 1204 / 1204 | 0% | 0 | 0 / 0 |
| blood vessel | 100% | 3470.29 | 1335 / 1335 | 0% | 0 | 0 / 0 |
| lymph node | 0% | 0 | 0 / 0 | 100% | 21.44 | 29 / 29 |
| muscle | 100% | 2873.71 | 803 / 803 | 0% | 0 | 0 / 0 |
| spleen | 100% | 1630.53 | 241 / 241 | 0% | 0 | 0 / 0 |
| tonsil | 0% | 0 | 0 / 0 | 100% | 13.83 | 45 / 45 |
| ureter | 0% | 0 | 0 / 0 | 100% | 5.59 | 1 / 1 |
| eye | 0% | 0 | 0 / 0 | 99% | 20.29 | 79 / 80 |
| heart | 95% | 1144.18 | 818 / 861 | 0% | 0 | 0 / 0 |
| peripheral blood | 84% | 1228.69 | 784 / 929 | 0% | 0 | 0 / 0 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| GO_0007165 | Biological process | signal transduction |
| GO_0006952 | Biological process | defense response |
| GO_0007173 | Biological process | epidermal growth factor receptor signaling pathway |
| GO_0045048 | Biological process | protein insertion into ER membrane |
| GO_0016192 | Biological process | vesicle-mediated transport |
| GO_0032435 | Biological process | negative regulation of proteasomal ubiquitin-dependent protein catabolic process |
| GO_0071816 | Biological process | tail-anchored membrane protein insertion into ER membrane |
| GO_0001782 | Biological process | B cell homeostasis |
| GO_0050821 | Biological process | protein stabilization |
| GO_0001881 | Biological process | receptor recycling |
| GO_0031397 | Biological process | negative regulation of protein ubiquitination |
| GO_0043529 | Cellular component | GET complex |
| GO_0005737 | Cellular component | cytoplasm |
| GO_0005783 | Cellular component | endoplasmic reticulum |
| GO_0016020 | Cellular component | membrane |
| GO_0005789 | Cellular component | endoplasmic reticulum membrane |
| GO_0031625 | Molecular function | ubiquitin protein ligase binding |
| GO_0005515 | Molecular function | protein binding |
| Gene name | CAMLG |
| Protein name | Guided entry of tail-anchored proteins factor (Calcium signal-modulating cyclophilin ligand) Calcium modulating ligand Guided entry of tail-anchored proteins factor CAMLG (Calcium signal-modulating cyclophilin ligand) |
| Synonyms | GET2 CAML |
| Description | FUNCTION: Required for the post-translational delivery of tail-anchored (TA) proteins to the endoplasmic reticulum . Together with GET1/WRB, acts as a membrane receptor for soluble GET3/TRC40, which recognizes and selectively binds the transmembrane domain of TA proteins in the cytosol . Required for the stability of GET1 . Stimulates calcium signaling in T cells through its involvement in elevation of intracellular calcium . Essential for the survival of peripheral follicular B cells (By similarity). . FUNCTION: Required for the post-translational delivery of tail-anchored (TA) proteins to the endoplasmic reticulum. Together with GET1/WRB, acts as a membrane receptor for soluble GET3/TRC40, which recognizes and selectively binds the transmembrane domain of TA proteins in the cytosol. Required for the stability of GET1. Stimulates calcium signaling in T cells through its involvement in elevation of intracellular calcium. Essential for the survival of peripheral follicular B cells. . |
| Accessions | ENST00000514518.1 D6RIW3 ENST00000297156.4 P49069 ENST00000677273.1 A0A7I2V3C5 ENST00000676829.1 ENST00000678771.1 A0A7I2V518 A0A7I2V377 |